Stiff-armed by a stubborn Actelion, J&J takes its check book and walks away, leaving an opening for Sanofi
And then it was over.
J&J kept it short and sweet this evening, announcing it has ended talks with Actelion about a possible buyout …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
